Abstract
Current evidence strongly implicates the chromosome translocation t(9;22) as the cause of chronic granulocytic leukemia (CGL). Therefore, the identification of the genetic aberrancy through either cytogenetic or molecular methods is a requirement for diagnosis. Furthermore, qualitative and quantitative methods of detecting t(9;22) are useful in monitoring response status and disease progression. Advances have been made in the management of the disease in its chronic phase, but the blast phase of CGL remains terminal. In this review, the available treatment options in chronic-phase CGL are discussed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
